Home Cart Sign in  
Chemical Structure| 227963-15-7 Chemical Structure| 227963-15-7

Structure of MK-0429
CAS No.: 227963-15-7

Chemical Structure| 227963-15-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

MK-0429 is a potent integrin antagonist with IC50s of 12.2 nM (α5β1 integrin) and 2.8 nM (αvβ3 integrin), respectively.

Synonyms: L-000845704

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of MK-0429

CAS No. :227963-15-7
Formula : C23H29N5O4
M.W : 439.51
SMILES Code : O=C(O)C[C@H](N1CCN(CCCC2=NC3=C(CCCN3)C=C2)C1=O)C4=CC=C(OC)N=C4
Synonyms :
L-000845704
MDL No. :MFCD27665469

Safety of MK-0429

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H360-H373
Precautionary Statements:P201-P202-P260-P280-P308+P313-P405-P501

Related Pathways of MK-0429

cytoskeleton

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00533650 Post-Menopausal Osteoporosis Phase 2 Completed - -
NCT00302471 Prostatic Neoplasms Phase 1 Completed - -

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.28mL

0.46mL

0.23mL

11.38mL

2.28mL

1.14mL

22.75mL

4.55mL

2.28mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
The prepared working fluid is recommended to be prepared now and used up as soon as possible in a short period of time. The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
 

Historical Records

Categories